News
TRDA
6.22
-4.31%
-0.28
Weekly Report: what happened at TRDA last week (0914-0918)?
Weekly Report · 3d ago
Weekly Report: what happened at TRDA last week (0907-0911)?
Weekly Report · 09/14 09:16
Major Investors Quietly Unload a Big Chunk of Entrada Therapeutics Shares
TipRanks · 09/10 02:01
Weekly Report: what happened at TRDA last week (0831-0904)?
Weekly Report · 09/07 09:15
Major Investors Quietly Unload a Big Chunk of Entrada Therapeutics Stock
TipRanks · 09/04 02:03
Analysts Conflicted on These Healthcare Names: Definitive Healthcare Corp (DH) and Entrada Therapeutics Inc (TRDA)
TipRanks · 09/03 11:30
Weekly Report: what happened at TRDA last week (0824-0828)?
Weekly Report · 08/31 09:16
Weekly Report: what happened at TRDA last week (0817-0821)?
Weekly Report · 08/24 09:17
Weekly Report: what happened at TRDA last week (0810-0814)?
Weekly Report · 08/17 09:17
Entrada Therapeutics price target raised to $11 from $10 at Roth Capital
TipRanks · 08/17 08:59
Analysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Entrada Therapeutics Inc (TRDA)
TipRanks · 08/12 19:10
Major Insider Moves Shake Up Entrada Therapeutics Inc. Stock
TipRanks · 08/11 02:01
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Janux Therapeutics Inc (JANX) and Entrada Therapeutics Inc (TRDA)
TipRanks · 08/10 10:40
Weekly Report: what happened at TRDA last week (0803-0807)?
Weekly Report · 08/10 09:16
Entrada Q2 Loss Shrinks; Data From Phase 1/2 Trials In DMD And DM1 Expected In '27
NASDAQ · 08/07 05:03
Analysts’ Top Healthcare Picks: Insulet (PODD), Entrada Therapeutics Inc (TRDA)
TipRanks · 08/05 20:20
Entrada Therapeutics reports Q2 results
Seeking Alpha · 08/05 18:19
Press Release: Entrada Therapeutics Reports -2-
Dow Jones · 08/05 11:00
Big Insider Moves Rock Entrada Therapeutics as Key Players Cut Their Stakes
TipRanks · 08/04 02:02
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 08/03 12:05
More
Webull provides a variety of real-time TRDA stock news. You can receive the latest news about Entrada Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.